A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.

Authors

Sadhna Shankar

MacroGenics, Inc., Rockville, MD

Sadhna Shankar , Alexander I. Spira , James Strauss , Liqin Liu , Ross La Motte-Mohs , Tony Wu , Syd Johnson , Ezio Bonvini , Paul A. Moore , Jon M. Wigginton , Jim Vasselli

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies.

First Author: Alexander M. Lesokhin

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.

First Author: Miguel Angel Villalona-Calero

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).

First Author: Tian Zhang

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.

First Author: Kenneth Desantes